# NXTC catalysts: NextCure, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/nxtc/catalysts

> NextCure, Inc. (NXTC) has 2 upcoming catalysts. The next is the AVR-001 trial start, early 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for NXTC?

NextCure, Inc. (NXTC) has 2 upcoming catalysts. The next is the AVR-001 trial start, early 2027. Press release filed with the SEC (EX-99): "A US IND for AVR-001 is open, and initiation of the Phase 2b study by Avere is anticipated in early 2027, with an expected readout in the first half of 2028." [Calendar and source filings](https://sec-api.dev/companies/nxtc/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-083326, https://www.sec.gov/Archives/edgar/data/1661059/000110465926083326/tm2620428d1_ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-07-14. Cite: https://sec-api.dev/companies/nxtc/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | NextCure, Inc. |
| Ticker | NXTC (Nasdaq) |
| SEC CIK | 1661059 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/nxtc |

## Cash runway

Cash $8.7M as of 2026-09-30; quarterly burn $12.1M; about 2.2 months of runway at that rate (XBRL company facts, accession 0001104659-26-125220).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb 2023 | [NC525 trial start](https://sec-api.dev/pdufa/nc525) | NXTC |  | completed | "In February 2023, we initiated a Phase 1 trial for NC525 to evaluate the safety and preliminary efficacy of NC525 in AML, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia (CMML)." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1661059/000110465925123304/tm2533949-1_424b5.htm)) |
| December 5, 2024 | [NextCure, Inc. NDA/BLA submission](https://sec-api.dev/companies/nxtc/catalysts) | NXTC |  | completed | "On December 5, 2024, NextCure, Inc. (the "Company") updated its corporate presentation to reflect that it has filed an Investigational New Drug Application for its product candidate LNCB74." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1661059/000155837024016026/nxtc-20241205x8k.htm)) |
| Jan 2025 | [SIM0505 trial start](https://sec-api.dev/pdufa/sim0505) | NXTC |  | completed | "First patient dosed in January 2025 in the Phase 1 trial, cleared cohort 3 in June 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000155837025010774/nxtc-20250807xex99d1.htm)) |
| January 10, 2025 | [NextCure, Inc. trial start](https://sec-api.dev/companies/nxtc/catalysts) | NXTC | cancer, today | completed | "On January 10, 2025, NextCure, Inc. (the "Company") issued a press release announcing that the first patient has been dosed in its Phase 1 study of LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) as a therapeutic for treating multiple cancers." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1661059/000155837025000099/nxtc-20250110x8k.htm)) |
| March 6, 2025 | [NextCure, Inc. earnings report](https://sec-api.dev/companies/nxtc/catalysts) | NXTC |  | completed | "Reports Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000155837025002396/nxtc-20250306xex99d1.htm)) |
| May 1, 2025 | [NextCure, Inc. earnings report](https://sec-api.dev/companies/nxtc/catalysts) | NXTC |  | completed | "Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000155837025006106/nxtc-20250501xex99d1.htm)) |
| Jun 2025 | [SIM0505 trial start](https://sec-api.dev/pdufa/sim0505) | NXTC |  | completed | "Investigational New Drug application transferred to NextCure in June 2025, with anticipated first patient dosed in the US within the third quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000155837025010774/nxtc-20250807xex99d1.htm)) |
| August 7, 2025 | [NextCure, Inc. earnings report](https://sec-api.dev/companies/nxtc/catalysts) | NXTC |  | completed | "Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000155837025010774/nxtc-20250807xex99d1.htm)) |
| Nov 2025 | [SIM0505 trial start](https://sec-api.dev/pdufa/sim0505) | NXTC |  | completed | "Higher dose cohort enrollment initiated in the ongoing open-label Phase 1 dose escalation study (NCT06774963), following the November 2025 protocol amendment announcement." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000110465926024121/nxtc-20260305xex99d1.htm)) |
| November 5, 2025 | [NextCure, Inc. earnings report](https://sec-api.dev/companies/nxtc/catalysts) | NXTC |  | completed | "Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000110465925107008/nxtc-20251105xex99d1.htm)) |
| March 5, 2026 | [NextCure, Inc. earnings report](https://sec-api.dev/companies/nxtc/catalysts) | NXTC |  | completed | "Reports Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000110465926024121/nxtc-20260305xex99d1.htm)) |
| Q2 2026 | [SIM0505 topline data readout](https://sec-api.dev/pdufa/sim0505) | NXTC |  | scheduled | "In October 2025, we announced dosing our first patient and expect to provide a Phase 1 dose escalation data readout in the second quarter of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1661059/000110465926024137/nxtc-20251231x10k.htm)) |
| Q2 2026 | [SIM0505 trial start](https://sec-api.dev/pdufa/sim0505) | NXTC |  | scheduled | "Initiation of Phase 1 dose optimization study in ovarian cancer expected in the second quarter of 2026 with a continued focus on PROC." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000110465926024121/nxtc-20260305xex99d1.htm)) |
| May 7, 2026 | [NextCure, Inc. earnings report](https://sec-api.dev/companies/nxtc/catalysts) | NXTC |  | completed | "Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000110465926057171/nxtc-20260507xex99d1.htm)) |
| August 6, 2026 | [NextCure, Inc. earnings report](https://sec-api.dev/companies/nxtc/catalysts) | NXTC |  | completed | "Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000110465926092025/nxtc-20260806xex99d1.htm)) |
| November 10, 2026 | [NextCure, Inc. earnings report](https://sec-api.dev/companies/nxtc/catalysts) | NXTC |  | completed | "Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000110465926125188/nxtc-ex99d1.htm)) |
| early 2027 | [AVR-001 trial start](https://sec-api.dev/pdufa/avr-001) | NXTC |  | scheduled | "A US IND for AVR-001 is open, and initiation of the Phase 2b study by Avere is anticipated in early 2027, with an expected readout in the first half of 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000110465926083326/tm2620428d1_ex99-1.htm)) |
| 1H 2028 | [AVR-001 topline data readout](https://sec-api.dev/pdufa/avr-001) | NXTC |  | scheduled | "A US IND for AVR-001 is open, and initiation of the Phase 2b study by Avere is anticipated in early 2027, with an expected readout in the first half of 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000110465926083326/tm2620428d1_ex99-1.htm)) |

## Drugs

- [AVR-001](https://sec-api.dev/pdufa/avr-001): 
- [NC525](https://sec-api.dev/pdufa/nc525): 
- [SIM0505](https://sec-api.dev/pdufa/sim0505): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/nxtc/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NXTC catalysts: NextCure, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/nxtc/catalysts

```bibtex
@misc{secapidev_companies_nxtc_catalysts_20261116,
  title        = {NXTC catalysts: NextCure, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/nxtc/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_nxtc_catalysts_20261116","title":"NXTC catalysts: NextCure, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/nxtc/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
